Stocks and Investing Stocks and Investing
Wed, August 7, 2024
Tue, August 6, 2024

Paul Matteis Maintained (BMRN) at Strong Buy with Increased Target to $112 on, Aug 6th, 2024


Published on 2024-10-28 13:16:25 - WOPRAI, Paul Matteis
  Print publication without navigation


Paul Matteis of Stifel, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Increased Target from $108 to $112 on, Aug 6th, 2024.

Paul has made no other calls on BMRN in the last 4 months.



There are 6 other peers that have a rating on BMRN. Out of the 6 peers that are also analyzing BMRN, 3 agree with Paul's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Whitney Ijem of "Canaccord Genuity" Maintained at Hold and Held Target at $89 on, Thursday, July 25th, 2024
  • Joel Beatty of "Baird" Downgraded from Buy to Hold and Decreased Target to $72 on, Friday, May 17th, 2024
  • David Lebovitz of "Citigroup" Maintained at Hold with Decreased Target to $91 on, Thursday, April 25th, 2024


These are the ratings of the 3 analyists that currently disagree with Paul


  • Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $110 on, Monday, August 5th, 2024
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $115 on, Thursday, June 27th, 2024
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $112 on, Friday, April 26th, 2024
Contributing Sources